Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- manufacturers
- ADTL-EI1712
-
- $223.00
-
2026-05-11
- CAS:2414916-45-1
- Purity:
- Supply Ability: 10g
|
| | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- Basic information |
| Product Name: | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- | | Synonyms: | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro-;ADTL-EI1712;ADTLEI1712,ADTL-EI-1712,ADTL EI1712;2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxamide | | CAS: | 2414916-45-1 | | MF: | C22H18Cl2N4O2S2 | | MW: | 505.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2414916-45-1.mol | ![Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- Structure](CAS/20210305/GIF/2414916-45-1.gif) |
| | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- Chemical Properties |
| density | 1.556±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 1 mg/ml,DMSO: 1 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml | | form | A crystalline solid | | pka | 11.86±0.20(Predicted) |
| | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- Usage And Synthesis |
| Uses | ADTL-EI1712 is a potent, orally active, and selective dual-target inhibitor of ERK1 and ERK5, inhibition rates of ERK1/5 at 1 μM are 93.54% and 89.35%, respectively. ADTL-EI1712 can induce regulated cell death, a form of cell death that relies on the activation of genetically encoded machinery, to overcome compensatory mechanism in specific cancer cells in vitro and in vivo[1]. | | Biological Activity | ADTL-EI1712 is a dual inhibitor of ERK1 and ERK5 (IC50s = 40.43 and 64.5 nM, respectively).1 It reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM. ADTL-EI1712 inhibits proliferation of HL-60 and MKN74, but not HeLa, cancer cells (IC50s = 1.26, 2.55, and >50 μM, respectively). It reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model when administered at a dose of 50 mg/kg per day. | | in vivo | ADTL-EI1712 (50 mg/kg, PO, once a day for 16 days) significantly inhibits the tumor volume in the xenograft mouse model of HL-60 and MKN-74 cells, while the antitumor effect of HeLa cells group was much weaker[1].
| | References | 1.Wang, G., Zhao, Y., Liu, Y., et al.Discovery of a novel dual-target inhibitor of ERK1 and ERK5 that induces regulated cell death to overcome compensatory mechanism in specific tumor typesJ. Med. Chem.63(8)3976-3995(2020) |
| | Thieno[2,3-c]pyridine-3-carboxamide, 2-[(2-chlorobenzoyl)amino]-6-[[(2-chlorophenyl)amino]thioxomethyl]-4,5,6,7-tetrahydro- Preparation Products And Raw materials |
|